Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib by Steverding, Dietmar & Wang, Xia
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
Parasites & Vectors
Open Access Short report
Trypanocidal activity of the proteasome inhibitor and anti-cancer 
drug bortezomib
Dietmar Steverding* and Xia Wang
Address: BioMedical Research Centre, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, NR4 7TJ, UK
Email: Dietmar Steverding* - dsteverding@hotmail.com; Xia Wang - xiawang@hotmail.com
* Corresponding author    
Abstract
The proteasome inhibitor and anti-cancer drug bortezomib was tested for in vitro activity against
bloodstream forms of Trypanosoma brucei. The concentrations of bortezomib required to reduce
the growth rate by 50% and to kill all trypanosomes were 3.3 nM and 10 nM, respectively. In
addition, bortezomib was 10 times more toxic to trypanosomes than to human HL-60 cells.
Moreover, exposure of trypanosomes to 10 nM bortezomib for 16 h was enough to kill 90% of the
parasites following incubation in fresh medium. However, proteasomal peptidase activities of
trypanosomes exposed to bortezomib were only inhibited by 10% and 30% indicating that the
proteasome is not the main target of the drug. The results suggest that bortezomib may be useful
as drug for the treatment of human African trypanosomiasis.
Findings
Human African trypanosomiasis or sleeping sickness is a
fatal disease caused by the protozoan parasite Trypano-
soma brucei. The parasites live and multiply extracellularly
in the blood and tissue fluids in the human host and are
transmitted by the bite of infected tsetse flies (Glossina
spp.). Millions of people living in 36 sub-Saharan coun-
tries are threatened with the disease and the estimated
number of infected people is currently between 50,000
and 70,000 [1]. There are only four drugs available for
chemotherapy of sleeping sickness and all show some
degree of toxic side effects [2]. In addition, drug resistance
in T. brucei is an increasing problem [3,4]. Moreover, at
the turn of the millennium, the production of anti-sleep-
ing sickness drugs was under threat as their manufacture
was not profitable [5]. Thus, new strategies for the devel-
opment of new drugs for treatment of sleeping sickness
are urgently needed.
One route for the discovery of new anti-sleeping sickness
drugs is the screening of existing drugs for trypanocidal
activities [6]. For example, agents that have been devel-
oped as potential anti-cancer drugs could also be of use
against human African trypanosomiasis as has been
shown for the ornithine decarboxylase inhibitor eflorni-
thine [7]. Proteasome inhibitors represent a new class of
anti-cancer drugs and have recently been shown to display
promising anti-trypanosomal activities [8-12]. In this
study, we investigated the effect of the proteasome inhib-
itor bortezomib (Fig. 1) on bloodstream forms of T. bru-
cei. Bortezomib (Velcade®) is a novel chemotherapeutic
agent for multiple myeloma and mantle cell lymphoma,
and was approved by the FDA for treatment of these
malignancies in 2003 and 2006, respectively [13].
The trypanocidal activity of bortezomib was determined
with T. brucei bloodstream forms 427-221a while the gen-
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eral cytotoxicity of the drug was evaluated with human
myeloid leukaemia HL-60 cells. The tests were analysed
by the Alamar Blue assay as described previously [14]. In
brief, cells were seeded in 24-well plates in a final volume
of 1 ml of appropriate culture medium (trypanosomes:
Baltz medium plus 16.7% heat-inactivated foetal bovine
serum [15]; HL-60 cells: RPMI 1640 plus 16.7% heat-inac-
tivated foetal bovine serum) containing various concen-
tration of bortezomib and 1% DMSO. Wells containing
medium and 1% DMSO served as controls. The initial
densities were 104/ml for trypanosomes and 105/ml for
HL-60 cells. After 24 h incubation, 100 μl Alamar Blue
(11.11 mg resazurin sodium salt in 100 ml PBS) was
added and the cells were incubated for a further 48 h so
that the total incubation time was 72 h. Then, the plates
were read on a microplate reader using a test wavelength
of 570 nm and a reference wavelength of 630 nm. The
50% growth inhibition (GI50) values, i.e. the concentra-
tion of the drug necessary to reduce the growth rate of
trypanosomes and HL-60 cells by 50% to that of controls,
was determined by linear interpolation according to the
method described in [16]. The minimum inhibitory con-
centration (MIC) values, i.e. the concentration of the drug
at which all trypanosomes and HL-60 cells were killed,
was determined microscopically.
Bortezomib showed a dose-dependent effect on the
growth of T. brucei bloodstream forms with a GI50 value of
3.3 nM and a MIC value of 10 nM (Fig. 2). For compari-
son, the trypanocidal activity of the commercial anti-
sleeping sickness drug melarsoprol was determined under
the same experimental conditions. Melarsoprol exhibited
a GI50 value of 3.8 nM and a MIC value of 100 nM (Fig. 2).
Thus, the trypanocidal activity of bortezomib was similar
to melarsoprol with respect to the GI50 value and was 10
times greater with respect to the MIC value. As can be
expected from a drug to treat hematologic malignancies,
bortezomib exhibited also cytotoxic activity against HL-
60 cells with a GI50 value of 26.7 nM and a MIC value of
100 nM (Fig. 2). The GI50 value of bortezomib for HL-60
cells is within the range of the average GI50 value of 7 nM
for the drug across 60 tumour cell lines (including HL-60
cells) [17]. Melarsoprol, on the other hand, was much less
toxic to HL-60 cells, displaying a GI50 value of 3260 nM
and a MIC value of 10,000 nM (Fig. 2). As a result, the
GI50 and MIC ratios of cytotoxic/trypanocidal activities
(selectivity indices) for bortezomib were less favourable
(GI50 ratio = 8; MIC ratio = 10) than that of the anti-sleep-
ing sickness drug melarsoprol (GI50 ratio = 860; MIC ratio
= 100).
To check whether the trypanocidal activity of bortezomib
is due to inhibition of the proteasome, the activity of this
multi-enzyme complex in trypanosomes exposed to the
drug was determined. In this experiment, 107 trypano-
somes/ml were incubated with or without 100 μM borte-
zomib for 2 h. After washing three times with PBS/1%
glucose, the trypanosomes were lysed in 10 mM Tris, 2
mM ATP, 0.1 mM EDTA, pH 7, 1 mM DTT, 0.2% NP-40
and centrifuged at 16000 × g. The chymotrypsin-like activ-
ity and the trypsin-like activity of the clarified supernatant
were assayed in 50 mM HEPES, pH 7.5 with 10 μM Suc-
LLVY-AMC and 10 μM Z-GGR-AMC, respectively. Surpris-
Chemical structure of bortezomib Figure 1
Chemical structure of bortezomib. Bortezomib ([(1R)-
3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbo-
nyl)amino]propanoyl}amino)butyl]boronic acid) is marketed 
as Velcade® by Millennium Pharmaceuticals and currently 
used to treat people with multiple myeloma.
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Effect of bortezomib and melarsoprol on the growth of  bloodstream forms of T. brucei and human myeloid leukaemia  HL-60 cells Figure 2
Effect of bortezomib and melarsoprol on the growth 
of bloodstream forms of T. brucei and human myeloid 
leukaemia HL-60 cells. Trypanosomes (open symbols) 
and HL-60 cells (closed symbols) were incubated with vary-
ing concentrations of bortezomib (triangles) and melarsoprol 
(circles). After 72 h of culture, cell viability and proliferation 
were determined with the colorimetric dye resazurin. Mean 
values ± SD of four experiments are shown.
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ingly, bortezomib inhibited the chymotrypsin-like activ-
ity and the trypsin-like activity of the proteasome in
trypanosomes only by 30% and 10%, respectively. Under
the same experimental conditions, the drug inhibited the
proteasomal chymotrypsin-like and trypsin-like activity in
HL-60 cells by 100% and 90%, respectively. These find-
ings indicate that the trypanocidal action of bortezomib is
most likely not the result from inactivation of the protea-
some.
For treatment of multiple myeloma, the recommended
dose and treatment schedule of bortezomib is 1.3 mg/m2
administered as a 3 to 5 second bolus intravenous injec-
tion on days 1, 4, 8 and 11 of a three week cycle, for up to
8 cycles [18]. Pharmacokinetic/pharmacodynamic studies
showed that on day 11 the mean plasma concentration of
bortezomib falls from 422 nM to 10 nM within 16 h of
administration of the drug [19]. As 10 nM is the MIC
value of bortezomib, we wanted to investigate whether
exposure of trypanosomes to 10 nM of the drug for 16 h
is long enough to kill the parasites. To this end, 5 × 105
trypanosomes/ml were treated with or without 10 nM
bortezomib for 16 h, then diluted to 104 cells/ml in fresh
medium for further incubation and counted every 24 h
using a Neubauer haemocytometer. For the first 48 h of re-
incubation, the densities of cultures containing trypano-
somes that had been exposed to bortezomib decreased
continuously (Fig. 3). Thereafter, the numbers of trypano-
somes started to increase but did not reach those of con-
trol cultures (Fig. 3). This result shows that treatment of
trypanosomes with 10 nM bortezomib for 16 h leads in
the killing of 90% of the parasites.
In conclusion, bortezomib has been shown to display
substantial trypanocidal activity. The current therapy
regime of bortezomib to treat cancer is probably not
applicable for treatment of sleeping sickness. The results
of this study indicate that a shorter treatment regime with
a higher dosage may be appropriate. Importantly, borte-
zomib can be also administered subcutaneously [19]
whereas most of the current anti-sleeping sickness drugs
have to be given intraveneously [21]. Before developing
bortezomib as an anti-sleeping sickness drug, animal
experiments would need to be performed to establish the
in vivo efficacy of this proteasome inhibitor. However, a
selectivity index of 10 may be regarded as insufficient for
proceeding to animal experiments. The Special Pro-
gramme for Research and Training in Tropical Diseases at
the World Health Organization (WHO/TDR) recom-
mends a selectivity index of >100 to pursue such animal
studies [22]. Compared with normal cells, however, the
cytotoxicity of bortezomib determined for HL-60 cells
may be overestimated. In addition, bortezomib may serve
as a lead for the development of analogues with improved
selectivity. Another possibility would be to use borte-
zomib in combination with the current drugs to treat
sleeping sickness. Such drug combination regimes may
lead to synergistic effects, in which lower amounts of
drugs sufficient to kill the parasites would lead to a reduc-
tion in toxicity.
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